At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Sep 1, 2026 at 09:05 ET
BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for hypophosphatasia (HPP), to its skeletal conditions portfolio. No financial terms were disclosed; the deal is a bolt-on pipeline addition for a $12.6B biotech with nine marketed products.
- Acquisition of Alesta Therapeutics closed; Alesta becomes a wholly owned subsidiary of BioMarin.
- Lead asset ALE1 is an oral small-molecule therapy for hypophosphatasia (HPP), a rare genetic bone disease.
- ALE1 is currently in a Phase 1/2a trial assessing safety, tolerability, and PK/PD in healthy volunteers and adults with HPP.
- No upfront payment, milestone, or royalty terms were disclosed in the press release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access